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Abstract 
A taskforce of the International Society of
Geriatric Oncology (SIOG) has recently sub-
mitted  recommendations  on  the  use  of  an-
thracyclines  in  elderly  patients.  Despite  the
aging of the population and the high propor-
tion of elderly individuals in the population of
patients  with  non-Hodgkin’s  lymphoma,  the
development  of  specialist  expertise  in  the
treatment  of  elderly  patients  with  cancer  is
relatively recent. Treatment of the elderly is
complex because they are a highly heteroge-
neous  population,  with  large  variations  in
health  status,  comorbidities  and  life  ex-
pectancy. In addition, these patients are gen-
erally more susceptible than young patients to
the  cardiotoxic  effects  of  anthracyclines.
Strategies for assessing elderly patients with
cancer, reducing the risk of congestive heart
failure, and assessing the cardiotoxic effects
of  treatments  are  discussed.  In  addition,  a
summary  of  the  SIOG  recommendations  is
presented. 
Introduction
The International Society of Geriatric On-
cology (SIOG) has the aim of fostering the de-
velopment of health professionals in the field
of  geriatric  oncology,  in  order  to  optimize
treatment for older adults with cancer. A SIOG
taskforce has recently submitted recommen-
dations on the position and use of anthracy-
clines in elderly patients. This paper discusses
some of the issues in treating cancer in the
elderly, and in using anthracyclines, and pres-
ents a summary of the SIOG recommendations
for their use. 
Aging of the population 
Across  the  world,  the  number  of  elderly
people in the population is growing, and the
median age of populations across the world
is  projected  to  increase  markedly  over  the
next 40 years.1 A large proportion of cancers
are more common in elderly than in younger
patients  [approximately  half  of  non-
Hodgkin’s  lymphomas  (NHL)  occur  in  pa-
tients older than 65 years of age; Figure 1].2
Thus,  with  an  aging  population,  the  inci-
dence  of  these  cancers  is  likely  to  grow.
Moreover, treatment of elderly patients with
cancer is not a simple matter, as they are a
highly heterogeneous patient population.3 In
addition,  elderly  patients  generally  have
greater  cardiac  risk  than  those  who  are
younger. There is therefore the need to de-
velop specialist expertise in the treatment of
elderly cancer patients. 
History of geriatric oncology 
as a specialism 
Interest in the treatment of cancer in the
elderly is a relatively recent specialism.4 It
first crystallized at the meeting Perspectives
on Prevention and Treatment of Cancer in the
Elderly, convened by the National Cancer In-
stitute and National Institute on Ageing in
1983. During the past 28 years, a great deal of
progress has been made. This included the
Venice  statement  about  poor  treatment  of
cancer in the elderly in 1990,5 the publication
of  the  first  edition  of  Comprehensive  Geri-
atric Oncology in 1998, formation of SIOG in
2000, publication of guidelines on the treat-
ment of geriatric patients with cancer,6,7 pub-
lication of the SIOG guidelines on compre-
hensive geriatric assessment8 and, in 2010,
the first publication of the Journal of Geri-
atric Oncology. 
The evidence base for treatment of
elderly patients with cancer 
Until recently, only a minority of elderly pa-
tients  with  cancer  were  enrolled  in  clinical
trials.  In  the  Southwestern  Oncology  Group
trials between 1993 and 1996, overall only 22%
of patients were at least 65 years of age, and
only 8-13% of patients were aged 70 years or
more.  This  discrepancy  was  particularly  no-
ticeable in some conditions that affect the eld-
erly,  such  as  lymphoma.9 This  practice  has
changed  somewhat  in  the  last  decade,  and
there  are  now  more  and  more  randomized,
controlled clinical trials specifically in elderly
patients,10 which  can  form  the  basis  of  evi-
dence-based guidelines (Figure 2).4
Definition and assessment 
of elderly patients 
The definition of elderly is often given as a
cut-off age for patients of 65 years. However,
this pension age definition is too simplistic. As
individuals age, depending both on their ge-
netic background and on the number of insults
their  body  has  been  subjected  to,  they  age
more  or  less  well.  Thus,  ‘the  elderly’  are  a
highly heterogeneous population.3 Patients of
the  same  chronological  age  have  different
levels  of  fitness,  comorbidities,  and  life  ex-
pectancy. This obviously has an effect on treat-
ment decisions, particularly when using toxic
therapies.  To  take  into  account  this  hetero-
geneity, and the factors that contribute to it,
patients may undergo a comprehensive geri-
atric assessment, which evaluates patients on
several  domains  of  aging:  cognition,  comor-
bidities, emotional conditions, function, geri-
atric syndromes, nutrition, pharmacy, and so-
cioeconomic conditions.6
The Comprehensive Geriatric Assessment
(CGA) is a well established tool for assessing
elderly  patients  to  establish  their  health
status, and risks of morbidity, mortality, and
toxicity.11 However, it is currently unclear to
what extent this assessment might help to
identify  patients  who  would  benefit  from
chemotherapy  with  anthracyclines.  The  as-
sessment can help describe how fit a patient
is, but some patients simply will not tolerate
the chemotherapy, and it is difficult to iden-
tify these patients before treatment.12 Never-
theless,  it  is  still  worth  assessing  patients
stringently. If an elderly patient has not been
fully  assessed,  some  issues,  in  addition  to
the cancer, may be missed that would affect
their  outcomes  over  the  next  few  years.
Moreover, it has been demonstrated that in-
terventions dictated by a CGA of the patient
reduced morbidity and mortality in patients
at risk of frailty.13
Health status or fitness as a guide
to treatment in the elderly 
The  concept  of  health-status  categories
may  be  useful  in  predicting  the  life  ex-
pectancy  of  patients.  In  a  study  of  cancer
screening, elderly patients were divided into
three  groups  according  to  their  health
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who  were  fit,  the  middle  two  quartiles  as
those with median health status (who had
some  minor  health  problems),  and  the
bottom quartile as those who were frail, and
had severe health problems.14 The group of
patients who were 80 years old and fit had a
median  life  expectancy  of  a  further  10.8
years, compared with 3.3 years for those who
were frail. This prognosis might well affect
the type of treatment a patient may be given,
and the decision of whether to give adjuvant
therapy  in  an  attempt  to  prolong  survival.
However,  there  are  currently  few  clinical
trial data on the efficacy and tolerability of
adjuvant treatments in patients who are 80
years old, so it is extremely difficult to make
evidence-based treatment decisions in this
patient population. 
Decisions on the types of treatments elderly
patients receive can be based on a general as-
sessment  of  their  health  status  and  fitness.
Elderly patients who are fit, or those who have
some problems that can be ameliorated by an
intervention, should in principle receive the
same treatment as that given to younger pa-
tients. Those who have a worse health status
and multiple problems that cannot be easily
improved should be given a geriatric-specific
intervention – i.e. they may receive some non-
aggressive  and/or  palliative  treatment.  De-
spite these general guidelines, it is difficult to
judge which categories patients fall into and
the most appropriate treatment strategy for an
individual. 
Factors limiting chemotherapeutic
treatment of the elderly 
There are some true limitations to the use
of  cytotoxic  chemotherapy  in  the  elderly.  A
key  one  is  renal  function,  as  many  of  the
drugs are excreted renally and may produce
toxicity problems when used in the elderly.
Other issues include liver function, drug dis-
tribution,  and  absorption,  marrow  reserves,
and neurological factors.3 In addition, elderly
patients  are  commonly  taking  several  dif-
ferent drugs, some of which may have poten-
tially dangerous interactions, so these must
be  considered  before  treatment.  Despite
these limitations, there is now evidence for
the benefits of chemotherapy in elderly pa-
tients  with  lymphoma,  as  discussed  else-
where in this issue (see Burchardt and Gis-
selbrecht in this supplement). 
Anthracycline-associated 
cardiotoxicity 
Cardiotoxicity is a known complication of
anthracycline  use,  not  only  for  elderly  pa-
tients.  Anthracyclines  produce  cardiotoxicity
through oxidative stress, causing multiple ir-
reversible  and  cumulative  damage  to  my-
ocytes. This can lead to rare acute toxicities,
and  more  often  to  dilated  cardiomyopathy,
which has an insidious subclinical onset, re-
sulting in systolic dysfunction and left-sided
congestive  heart  failure  (CHF).  There  are
some treatments that can be used to palliate
this condition, but it can lead to severe mor-
bidity and death in some patients.15,16
Cardiotoxicity in elderly patients 
Cardiomyopathy as a result of doxorubicin
therapy has a worse outcome than idiopathic
cardiomyopathy.17 In  addition,  elderly  pa-
tients  are  more  susceptible  than  younger
ones to the cardiotoxic effects of anthracy-
clines, because their hearts have probably al-
ready  received  damage,  so  they  are  more
likely to develop heart failure at lower cumu-
lative doses of doxorubicin.18 Cardiotoxicity
is a particularly marked problem in patients
who  have  received  adjuvant  chemotherapy
for  breast  cancer,19 as  the  development  of
cardiac problems in the future may outweigh
the benefits of the initial treatment. In this
context, curative treatment for NHL is quite
analogous  to  the  adjuvant  treatment  of
breast cancer.
Recognizing cardiotoxicity 
in elderly patients 
There are several reasons why it is diffi-
Figure 2. Number of randomized, controlled clinical trials in elderly patients (>65 years of
age) with cancer over the past 20 years (using the Medline search terms: cancer/elderly;
title/abstract; +65; randomized controlled trial).4 Reprinted from Aapro MS. Launching
the Journal of Geriatric Oncology: a historical milestone. J Geriatr Oncol 2010;1:2-3,
©2010 with permission from Elsevier.
Figure 1. Number of cases and rate of hematologic disorders and solid tumors per 100,000
population, by patient age at diagnosis.2 Reprinted with permission from Cancer Research
UK, http://info.cancerresearchuk.org/cancerstats/types/nhl/incidence, October 2010.
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Articlecult to recognize either pre-existing or an-
thracycline-related  toxicity  in  elderly  pa-
tients. In general, physicians may not reli-
ably  recognize  common  adverse  effects  of
chemotherapy.20 In addition, elderly patients
often  have  several  non-treatment-related
symptoms that may mask or mimic the symp-
toms of CHF. The classic CHF symptom triad
of dyspnea, lower extremity edema, and fa-
tigue  are  all  common  in  the  elderly  for  a
number of reasons (e.g. presence of chronic
obstructive  pulmonary  disease,  obesity,
drug-induced  or  vascular  edema,  cirrhosis,
sleep apnea, or cancer) in addition to heart
failure. Thus, it can be difficult to identify
the cause of symptoms and signs. In addi-
tion, patients may not report new symptoms
to  their  clinicians,  because  they  consider
them part of their chemotherapy or under-
lying disease. 
There  are  several  potential  indicators  of
cardiac damage in patients given cardiotoxic
treatments. Some studies have indicated that
changes in troponin I immediately and after
chemotherapy  predict  left-ventricular  dys-
function.21 However,  other  research  groups
have argued that this is not the most appro-
priate measure.22 Brain natriuretic peptide,
which is a marker of volume overload, may
also  be  an  effective  marker  of  subsequent
myocardial damage.23 Another approach is to
measure  cardiotoxicity  using  echocardiog-
raphy  or  multi-gated  acquisition  (MUGA)
scans. Many cardiologists favor the use of left
ventricular ejection fraction (LVEF) to mon-
itor cardiotoxicity.24 However, this measure
is limited by the fact that it is not sensitive,
and produces different measures of LVEF de-
pending on the cardiologist conducting the
examination. Moreover, these tests only de-
tect cardiotoxicity once it has occurred and
manifested  as  left  ventricular  dysfunction,
whereas blood tests may detect cardiotoxicity
at an earlier stage. 
Reducing the risk of congestive
heart failure 
There are several strategies for reducing
the possibility of cardiotoxicity. Dexrazoxane
is a chelating agent that has been shown to
reduce  doxorubicin-associated  cardiomy-
opathy and is available for this use in some
countries.25 Antioxidants have also been con-
sidered  as  preventive  agents,  but  there  is
little evidence that these are effective. Once
the first signs of toxicity are observed, early
intervention with angiotensin-converting en-
zyme  (ACE)  inhibitors  and  possibly  beta
blockers may help these patients. An alterna-
tive strategy is not to treat cardiotoxicity once
it  has  developed,  but  to  use  anthracyclines
that  are  not  cardiotoxic,  which  provide  the
same  efficacy,  but  a  reduced  or  no  risk  of
long-term cardiotoxicity. The use of liposomal
anthracyclines has been shown to reduce the
cardiotoxicity  of  anthracycline  treatment,
compared with the conventional forms.26
SIOG recommendations for 
anthracycline use in elderly
patients
27*
Before treatment 
• Recommend rigorous screening to exclude
patients at unacceptably high cardiac risk
(level 1a evidence).
• Propose taking a comprehensive patient his-
tory, comprising current signs or history of
CHF, cardiovascular comorbidity (i.e. hyper-
tension,  diabetes,  or  coronary  artery  dis-
ease), and prior exposure to anthracyclines
for this or previous malignancy (all level 1a).
Anthracycline treatment 
• Recommend that clinicians do not exceed
the  recommended  upper  cumulative  dose
(level 1a).
• Propose a reduction in maximum cumula-
tive dose (level 5).
• Recommend using a less cardiotoxic thera-
py (level 1a). 
• Propose possible ways of reducing the level
of cardiotoxicity: 
– use of continuous infusion (level 1a)
– use of epirubicin (level 1a)
– use of dexrazoxane (level 1b, level 5 in
the elderly)
– use of liposomal anthracycline formula-
tions (level 1b, level 5 in the elderly) 
– sequential  administration  of  conven-
tional anthracyclines and trastuzumab in
human epidermal growth factor receptor-
2-positive breast cancer (level 1b, level 5
in the elderly).
Monitoring of cardiotoxicity 
• Recommend regular monitoring of cardiac
function, signs, and symptoms (level 1a).
• Propose  measurement  of  LVEF  by  ultra-
sound  (preferred,  level  5)  or  MUGA  scan
(use the same method through follow-up)
every 2-3 cycles of anthracyclines (level 1a).
• Propose: 
– special attention needed if drop in LVEF
exceeds  10%,  even  if  remaining  within
normal range (level 5)
– long-term follow-up (level 1a). 
Managing cardiac risk 
• Recommend interventions to reduce cardio-
vascular risk (level 1a). 
• Proposed ways to achieve this: 
– early management of dysfunction (level
1a) 
– lifestyle modifications (i.e. smoking ces-
sation,  regular  exercise,  weight  loss
where appropriate) (level 1a)
– beta blockers and ACE inhibitors (level 1a)
– reduced lipid levels (level 1a).
Conclusions
The  treatment  of  elderly  patients  with
cancer is a complex area. There is currently in-
sufficient evidence to allow the application of
specific  regimens  in  geriatric  oncology,  and
the impact of old age on cardiac problems is
complex and poorly understood. It is important
to  refine  treatment  algorithms  for  older  pa-
tients to ensure they receive optimal therapy.
In addition, when using highly effective drugs
such as anthracyclines, it is necessary to take
into account the patient’s status and keep in
mind their best interests, particularly in terms
of  their  long-term  life  expectancy.  Effective
and practical assessment tools are needed to
realize this vision. 
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